Erasca (ERAS) Preferred Stock Liabilities (2020 - 2021)
Erasca posted quarterly Preferred Stock Liabilities of $340.8 million for Q2 2021, up 88.23% year-on-year from $181.0 million in Q2 2020, and little changed on a QoQ basis from $340.8 million in Q1 2021.
Erasca (ERAS) has 2 years of Preferred Stock Liabilities data on file, last reported at $340.8 million in Q2 2021.
- For the quarter ending Q2 2021, Preferred Stock Liabilities rose 88.23% year-over-year to $340.8 million; the trailing twelve-month figure through Jun 2021 stood at $340.8 million (up 88.23% YoY), and the FY2020 full-year result was $221.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q2 2021 stood at $340.8 million, roughly flat from $340.8 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $340.8 million in Q1 2021 and bottomed at $181.0 million in Q2 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Erasca | 4.21 Bn | 3.97 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 340.80 Mn |
| Mar 31, 2021 | 340.80 Mn |
| Dec 31, 2020 | 221.41 Mn |
| Sep 30, 2020 | 191.40 Mn |
| Jun 30, 2020 | 181.05 Mn |